Clinical Development Strategy for a Selective CB2 Agonist on Microglia for Alzheimer’s Disease
9:00 am - Wednesday 15th October 2025
- Presentation of a selective CB2 receptor agonist acting on microglial cells to improve neuronal functions in Alzheimer’s Disease
- Overview of ongoing and planned clinical trial development focusing on inflammatory effects
- Review strategies to ensure maintenance of avoiding CB1 targeting throughout clinical development
NEW DATA
